The Uromigos
Advertisement
Tian Zhang joins the podcast to give an overview of some of the panels presented at this year's IKCS meeting.
Monty Pal, Toni Chouieri, and Tian Zhang join Tom and Brian to discuss CONTACT-03, TiNivo-2, IO-based therapy, and more.
Brian is joined by Drs. Agarwal, Dorff, McKay, and Morris to review the state of radioligand therapy.
Tom is joined by Drs. Chang, Daneshmand, and Grivas to discuss new therapies in NMIBC and BCG-refractory NMIBC.
Silke Gillessen, MD, PhD recaps some of the kidney, bladder, and prostate cancer data from this year's ESMO meeting.
Brian and Tom give details on the various panels that will take place at The Uromigos Live & Unplugged 2023.
Dr. Kevin Kelly discusses the AMG509 phase 1 study of xaluritamig, a bispecific T cell engager, for prostate cancer.
Xinan Sheng, MD, joins the podcast to discuss the RENOTORCH trial on toripalimab plus axitinib for advanced RCC.
Michiel Van der Heijdan, MD, PhD, discusses EV-302 and CheckMate-901 on EV plus pembrolizumab and nivolumab plus ipilimumab.
Yohann Loriot, MD, PhD, gives an update on the use of erdafitinib within the THOR randomized phase 3 trial.
Dr. Lisa Pickering discusses 3 different renal cancer abstracts that were presented at ESMO 2023.
Dr. Brad McGregor discusses the DAD trial on sacituzumab govitecan plus enfortumab vedotin for the treatment of mUC.
Louise Emmett discusses the phase 2 ENZA-p trial presented at ESMO 2023 on enzalutamide and 177Lu-PSMA-617 for mCRPC.
Silke Gillessen, MD, PhD joins us to discuss the upcoming ESMO conference and panels of interest to look out for.
Dr. Nick James discusses the optimal patients to undergo radiotherapy for localized prostate cancer.
Dr. Michalski discusses brachytherapy techniques in prostate cancer, plus his work on a recent JCO article on the topic.
Jim Catto, PhD, FRCS, joins The Uromigos to discuss the 17-year follow-up data from the PROTECT prostate cancer study.
Dr. Toni Choueiri discusses progress in systemic therapy for papillary renal cell carcinoma, as well as personalized therapy.
Dr. Susan F. Slovin discusses her recent paper that examined abiraterone with and without cabazitaxel for mCRPC.
Matt Galsky continues his discussion on ctDNA in bladder cancer and covers topics such as candidate versus panel approaches.
Advertisement
630 Madison Ave.
Manalapan, NJ 07726
© 2023 Mashup Media, LLC. All rights reserved.